Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03737318 · ClinicalTrials.gov registry record · NA

Correcting Residual Errors With Spectral, Ultrasound, Traditional Speech Therapy

A NA study, sponsored by New York University.

Completed
Registry status
NA
Development phase
108
Enrollment target

NCT03737318: Completed NA study, sponsored by New York University.

NCT03737318 is a NA study that has completed, run by New York University. The registered enrollment target is 108 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03737318, a NA study, has completed, sponsored by New York University.

COMPLETED
Registry status
NA
Development phase
108 participants
Enrollment target

Study Summary

Children with speech sound disorder show diminished accuracy and intelligibility in spoken communication and may thus be perceived as less capable or intelligent than peers, with negative consequences for both socioemotional and socioeconomic outcomes. While most speech errors resolve by the late school-age years, between 2-5% of speakers exhibit residual speech errors (RSE) that persist through adolescence or even adulthood, reflecting about 6 million cases in the US. Both affected children/families and speech-language pathologists (SLPs) have highlighted the critical need for research to identify more effective forms of treatment for children with RSE. In a series of single-case experimental studies, research has found that treatment incorporating technologically enhanced sensory feedback (visual-acoustic biofeedback, ultrasound biofeedback) can improve speech in individuals with RSE who have not responded to previous intervention. A randomized controlled trial (RCT) comparing traditional vs biofeedback-enhanced intervention is the essential next step to inform evidence-based decision-making for this prevalent population. Larger-scale research is also needed to understand heterogeneity across individuals in the magnitude of response to biofeedback treatment. The overall objective of this proposal is to conduct clinical research that will guide the evidence-based management of RSE while also providing novel insights into the sensorimotor underpinnings of speech. The central hypothesis is that biofeedback will yield greater gains in speech accuracy than traditional treatment, and that individual deficit profiles will predict relative response to visual-acoustic vs ultrasound biofeedback. This study will enroll n = 118 children who misarticulate the /r/ sound, the most common type of RSE. This first component of the study will evaluate the efficacy of biofeedback relative to traditional treatment in a well-powered randomized controlled trial. Ultrasound and visual-a

Primary Outcome

F3-F2 distance is a number (in Hz) that reflects how close a child's /r/ sound is to a typical adult-like /r/. Smaller numbers indicate more accurate /r/ production; larger numbers indicate a distorted /r/. In typical peers, accurate /r/ is roughly \~500 Hz, whereas distorted /r/ values are often \>1000 Hz. During Phase I (3 sessions over \~1 week), children produced /r/ in syllables/words. For this Outcome, we report change across sessions: a single model-based estimate of how much F3-F2 decrea

Interventions

  • BEHAVIORAL Traditional articulation treatment
  • BEHAVIORAL Biofeedback-ultrasound
  • BEHAVIORAL Biofeedback--visual-acoustic

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2019-03-01
Est. Completion 2024-08-31
Phase NA
New York University

83 total trials

What the finished NCT03737318 record still lists

NCT03737318 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 3 interventions - of which Traditional articulation treatment is the first listed.

NCT03737318 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03737318 about?

NCT03737318 is a clinical study titled "Correcting Residual Errors With Spectral, Ultrasound, Traditional Speech Therapy". Children with speech sound disorder show diminished accuracy and intelligibility in spoken communication and may thus be perceived as less capable or intelligent than peers, with negative consequences for both socioemotional and socioeconomic outcomes. While most speech errors resolve by the late sc...

What is the current status of trial NCT03737318?

This trial is currently completed. It is a NA study. The enrollment target is 108 participants. The study started on 2019-03-01. Estimated completion is 2024-08-31.

What interventions are being tested in trial NCT03737318?

The interventions under investigation include: Traditional articulation treatment (BEHAVIORAL), Biofeedback-ultrasound (BEHAVIORAL), Biofeedback--visual-acoustic (BEHAVIORAL).

Who is sponsoring clinical trial NCT03737318?

This trial is sponsored by New York University, which has 83 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03737318's enrollment target sits among peer trials

108 825th of 2000 higher than 1,171 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02703207 · 108 participants · NA

    Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD

  • NCT02744677 · 108 participants · NA

    COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

  • NCT02781883 · 108 participants · Phase 2

    Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

  • NCT03848663 · 108 participants · NA

    Visual Remapping to Aid Reading With Field Loss

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03737318, the US trial registry maintained by the National Library of Medicine. NCT03737318 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.